MOLECULAR ICE CONTROL FOR ENGINEERED TISSUES

Information

  • Research Project
  • 6608591
  • ApplicationId
    6608591
  • Core Project Number
    R43HL069218
  • Full Project Number
    5R43HL069218-02
  • Serial Number
    69218
  • FOA Number
    PAR-01-006
  • Sub Project Id
  • Project Start Date
    2/1/2002 - 22 years ago
  • Project End Date
    7/31/2004 - 20 years ago
  • Program Officer Name
    LUNDBERG, MARTHA
  • Budget Start Date
    2/1/2003 - 21 years ago
  • Budget End Date
    7/31/2004 - 20 years ago
  • Fiscal Year
    2003
  • Support Year
    2
  • Suffix
  • Award Notice Date
    -

MOLECULAR ICE CONTROL FOR ENGINEERED TISSUES

DESCRIPTION (provided by applicant): Long term preservation is crucial as an enabling technology for tissue engineering. Cryopreservation would provide an ideal solution to this need except that ice crystallization in complex multicomponent tissues causes injury to the cells and the extracellular matrix rendering the tissue nonfunctional. Vitreous cryopreservation that stabilizes the biosystem as a glass, thereby avoiding ice crystallization, leads to markedly improved cryopreservation. However, vitrification is not easily achieved in bulk samples relevant to clinical applications because of constraints on attaining sufficiently high cooling and warming rates to preclude ice formation. The ultimate goal of banking natural and engineered tissues using vitrification will be achieved only if adequate methods of controlling ice growth are devised. This study is focused on a novel approach to controlling ice in complex tissues by combining conventional cryoprotective agents with synthetic ice blocker (SIB) molecules and naturally-occurring antifreeze peptides. SIBs are a series of proprietary molecules designed on the basis of molecular-modeling studies to limit ice nucleation and growth. Existing and newly designed SIBs will be applied to the challenge of designing solutions for vitrifying bulk samples without ice damage and showing feasibility for the long-term storage of vascular grafts. PROPOSED COMMERCIAL APPLICATIONS: The technology development proposed in this application will enable the emerging tissue engineering industry to make more effective and efficient use of new developments in tissue preservation. Current tissue and cell storage methods have well-recognized technical problems associated with ice formation. A primary goal of Organ Recovery Systems, Inc. (ORS) is development of methods and devices for storage and transportation of biological materials, tissues and organs for both in vitro and in vivo use. Ultimately, the success of both allogeneic transplantation and tissue engineering depends upon the availability of practical product storage and transportation methods. The only methods currently used for unlimited storage and stabilization of cells and tissues involve the application of cryobiology. The potential markets are enormous. Cryopreservation methods, which result in retained viability and function, will be licensed to the tissue engineering industry.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R43
  • Administering IC
    HL
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    107031
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    837
  • Ed Inst. Type
  • Funding ICs
    NHLBI:107031\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ORGAN RECOVERY SYSTEMS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    CHARLESTON
  • Organization State
    SC
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    294035000
  • Organization District
    UNITED STATES